MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss
-$2,822M
(20.75%↑ Y/Y)
COVID19
$1,810M
RSV
$8M
Loss before income
taxes
-$2,768M
(23.26%↑ Y/Y)
Provision for (benefit
from) tax provision
$54M
(217.39%↑ Y/Y)
Interest income
$314M
(-26.12%↓ Y/Y)
Product Sales
$1,818M
(-41.52%↓ Y/Y)
Product And Service
Other
$126M
(-0.79%↓ Y/Y)
Loss from operations
-$3,074M
(22.08%↑ Y/Y)
Total revenue
$1,944M
(-39.93%↓ Y/Y)
Other expense, net
-$8M
(90.80%↑ Y/Y)
Total operating
expenses
$5,018M
(-30.12%↓ Y/Y)
Research and development
$3,132M
(-31.06%↓ Y/Y)
Selling, general and
administrative
$1,018M
(-13.29%↓ Y/Y)
Cost of sales
$868M
(-40.71%↓ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
Master Final R&D Day 2021 Slides (09
Moderna, Inc. (MRNA)
Master Final R&D Day 2021 Slides (09
Moderna, Inc. (MRNA)